The table below shows Celldex Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$65.59M
-$54.37M
-$40.64M
-$28.57M
-$24.53M
-$18.08M
Capital expenditure
$1.64M
$265.00K
$344.00K
$585.00K
$575.00K
$567.00K
Investing cash flow
$72.12M
$42.95M
-$315.21M
$52.57M
$10.38M
$43.49M
Dividends paid
-
-
-
-
CLDX operating cash flow (10-K history)
Celldex Therapeutics, Inc. reported operating cash flow of -$210.94M for fiscal year 2025. That is down 33.7% from -$157.78M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$113.04M (FY 2016) to -$210.94M. Figures come from the company's audited annual reports as filed with the SEC.
